Analyst firms · H.C. Wainwright · NTLA

H.C. Wainwright NTLA price target and rating history

Intellia Therapeutics Inc. (NTLA) · Health Care

H.C. Wainwright rates Intellia Therapeutics Inc. (NTLA) Buy with a $30 price target, as of its latest action on Mar 5, 2025. It has published 3 rating actions on NTLA since June 2021, including 0 upgrades and 0 downgrades.

Current rating
Buy
Price target
$30
Median target, all firms
Too few
Actions on NTLA
3

H.C. Wainwright price target on NTLA

$182$106$3020222023202420252026
H.C. Wainwright price target on NTLA, each point a stated target, June 2021 to March 2025.

Every H.C. Wainwright rating on NTLA

How other firms rate NTLA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysUnderweight$8Oct 6, 2026
Wolfe ResearchUnderperform$9Jul 16, 2026
William BlairOutperformMar 2, 2026

Questions about H.C. Wainwright and NTLA

What is H.C. Wainwright's price target for NTLA?
H.C. Wainwright's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $30, from its action on Mar 5, 2025.
What is H.C. Wainwright's rating on NTLA?
H.C. Wainwright rates NTLA Buy, a bullish rating, as of Mar 5, 2025.
When did H.C. Wainwright last change its view on NTLA?
On Mar 5, 2025, H.C. Wainwright starts coverage at Buy, price target $30.

More NTLA rating histories

All H.C. Wainwright ratingsNTLA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.